Vertex Pharmaceuticals Inc. / MA (VRTX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Vertex Pharmaceuticals Inc. / MA’s revenue went from $1.7B in fiscal 2016 to $12.0B in fiscal 2025, growth of about 24.2% a year.
Net income in fiscal 2025 was $4.0B, a net margin of 32.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $13.0B and net income $4.0B.
Free cash flow was $3.2B in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count rose 5% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.0B | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B | $6.2B | $4.2B | $3.0B | $2.5B | $1.7B |
| Gross profit | $11.1B | $10.3B | $9.5B | $8.6B | $7.9B | $6.7B | $5.5B | $3.6B | $2.6B | $2.2B | $1.5B |
| Operating income | $4.3B | $4.2B | -$233M | $3.8B | $4.3B | $2.8B | $2.9B | $1.2B | $635M | $123M | $10M |
| Net income | $4.0B | $4.0B | -$536M | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263M | -$112M |
| EPS (diluted) | $15.53 | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | $-0.46 |
| R&D | $4.2B | $3.9B | $3.6B | $3.2B | $2.5B | $3.1B | $1.8B | $1.8B | $1.4B | $1.3B | $1.0B |
| Revenue growth | — | +8.9% | +11.7% | +10.5% | +17.9% | +22.1% | +49.1% | +36.6% | +22.5% | +46.2% | +64.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.7B | $3.6B | -$493M | $3.5B | $4.1B | $2.6B | $3.3B | $1.6B | $1.3B | $845M | $236M |
| Capital spending | -$492M | -$438M | -$298M | -$200M | -$205M | -$235M | -$260M | -$75M | -$95M | -$99M | -$57M |
| Free cash flow | $3.2B | $3.2B | -$790M | $3.3B | $3.9B | $2.4B | $3.0B | $1.5B | $1.2B | $746M | $180M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $1.1B | $2.0B | $1.2B | $428M | $0 | $1.4B | $539M | $186M | $350M | $0 | $0 |
| Stock-based pay | $669M | $686M | $698M | $581M | $491M | $441M | $430M | $360M | $325M | $293M | $241M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $6.6B | $6.1B | $11.2B | $10.8B | $7.5B | $6.7B | $3.8B | $3.2B | $1.7B | $1.2B |
| Debt | — | $1.9B | $1.6B | $382M | $428M | $411M | $361M | $96M | — | $0 | $300M |
| Equity | — | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B | $8.7B | $6.1B | $4.4B | $2.0B | $1.2B |
| Total assets | — | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B | $11.8B | $8.3B | $6.2B | $3.5B | $2.9B |
| Shares (diluted) | 255M | 258M | 258M | 260M | 259M | 260M | 263M | 261M | 259M | 253M | 245M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 85.5% | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% |
| Operating margin | 33.2% | 34.8% | -2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% |
| Net margin | 30.7% | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% |
| FCF margin | 24.7% | 26.6% | -7.2% | 33.8% | 44.0% | 31.8% | 48.2% | 35.9% | 38.6% | 30.0% | 10.5% |
| ROIC | — | 17.3% | -1.0% | 17.6% | 23.6% | 22.7% | 27.5% | 16.3% | 11.3% | 4.8% | 0.5% |
| ROE | — | 21.2% | -3.3% | 20.6% | 23.9% | 23.2% | 31.2% | 19.3% | 47.3% | 13.0% | -9.7% |
Frequently asked questions
What is Vertex Pharmaceuticals Inc. / MA’s annual revenue?
$12.0B in fiscal 2025 and $13.0B over the twelve months to September 30, 2026.
How much profit does Vertex Pharmaceuticals Inc. / MA make?
Net income was $4.0B in fiscal 2025 (net margin 32.9%).
Is Vertex Pharmaceuticals Inc. / MA’s revenue growing?
Yes: revenue rose 8.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.